On December 9, 2024 Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, reported a poster for preclinical data on CID-078, a first-in-class oral macrocycle cyclin A/B RxL inhibitor, will be presented at the San Antonio Breast Cancer Symposium 2024 (Press release, Circle Pharma, DEC 9, 2024, View Source [SID1234648895]). The event, which runs from December 10-13, brings together global leaders in breast cancer research and treatment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster presentation details are below:
Author: Molina et al
Title: CID-078, a first-in-class oral cyclin A/B-RxL inhibitor,
elicits anti-tumor activity in breast cancer patient-derived xenograft models
Poster Number: P2-05-29
Date and Time: December 11, 2024, from 5:30-7:00 PM CST
The digital poster can be viewed here.
The pre-clinical data showed CID-078 demonstrated single agent antitumor activity with CID-078 in preclinical models of triple-negative breast cancer (TNBC) and estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer following CDK4/6 inhibitor (CDK4/6i) therapy. In vivo activity was correlated with E2F1 and separase (ESPL1) expression and consistent with the proposed mechanism of action.
Further, treatment with CID-078 increased phosphorylation of separase in sensitive breast cancer patient-derived xenograft (PDX) models. These findings suggest that CID-078 may offer a novel treatment option for patients with Triple Negative Breast Cancer or patients with ER+/HER2- breast cancer following CDK4/6i therapy.
Circle Pharma is evaluating CID-078 in a multi-center Phase 1 clinical trial (NCT06577987), which aims to assess safety, tolerability, and preliminary efficacy in patients with advanced cancers, including TNBC and ER+/HER2- breast cancer.
About CID-078, Circle Pharma’s Cyclin A/B RxL Inhibitor Program
CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma’s cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center phase 1 clinical trial (NCT06577987) is currently enrolling patients.